AngioDynamics (NASDAQ:ANGO) reported net sales of $78.7 million in the first quarter of fiscal 2024, a modest increment of 5.7% on a pro-forma basis when Dialysis and BioSentry sales are excluded.
Interestingly, the company’s sales break into two streams: Medtech and Medical Devices. Medtech, the lion’s share of the revenue, posted a 13.3% YoY increase to $25.9 million whereas Med Devices moved at a glacial pace, registering a mere 2.3% growth to $52.8 million.
Despite the sluggish headline numbers, AngioDynamics managed to surprise analysts by exceeding analysts consensus estimate with a loss of $0.12.
The company has a history of beating or closely aligning with analysts’ expectations and has surpassed the consensus EPS estimates twice in the past fiscal year so this came as a surprise, causing the share price to drop.
Financials & Growth
The company’s gross margin of 50.9% showed a slight decline on a pro-forma basis year-over-year. Despite inflationary pressures on labor and raw materials, the Med Tech business improved its gross margin by 1.5%, reaching 64.7%.
The healthtech firm ended the quarter with over $57 million in cash and cash equivalents, indicating strong liquidity reserves.
For investors seeking new innovations from the firm, one such example is NanoKnife, which recorded disposable sales of $4.3 million, representing growth of 34.5%.
Excluding sales of Dialysis and BioSentry, international net sales saw an impressive 25.7% increase compared to the prior year.
What Does The Future Look Like?
The current consensus EPS estimate for the coming quarter is a loss of $0.08 on $81.98 million in revenues. For the current fiscal year, the estimate is a loss of $0.33 on $328.56 million in revenues.
In spite of the optimistic outlook, AngioDynamics has underperformed this year, with shares dropping by almost 45% compared to the S&P 500’s double digit percentage gain.
The Medtech sector and international market are bustling with potential for Angiodynamics, but its stock performance suggest a wary outlook is best. The company’s dual nature, combined with its Q1 2024 performance, means that investors need to view the stock with a skeptical eye for now.
#1 Stock For The Next 7 Days
When Financhill publishes its #1 stock, listen up. After all, the #1 stock is the cream of the crop, even when markets crash.
Financhill just revealed its top stock for investors right now... so there's no better time to claim your slice of the pie.
See The #1 Stock Now >>The author has no position in any of the stocks mentioned. Financhill has a disclosure policy. This post may contain affiliate links or links from our sponsors.